tiprankstipranks
Trending News
More News >

YiChang HEC ChangJiang Pharmaceutical Launches Innovative Hepatitis C Drug

Story Highlights
  • YiChang HEC ChangJiang focuses on innovative drug development in China’s healthcare market.
  • The company launches Encofosbuvir Tablets, boosting its position in the hepatitis C market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
YiChang HEC ChangJiang Pharmaceutical Launches Innovative Hepatitis C Drug

Don’t Miss TipRanks’ Half-Year Sale

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) has issued an announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the approval and upcoming launch of its Encofosbuvir Tablets, a Class I innovative drug for treating Hepatitis C. This approval marks a significant milestone for the company, enhancing its competitive edge in the hepatitis C treatment market and reinforcing its position as a leader among innovative pharmaceutical companies in China.

More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in China, focusing on innovative drug development. The company has a strong presence in the primary healthcare market, particularly in the hepatitis C drug sector, with a comprehensive portfolio of drug products.

YTD Price Performance: 0.84%

Average Trading Volume: 3,014,209

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.48B

For a thorough assessment of 1558 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1